-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Typhax in Typhoid Fever
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Typhax in Typhoid Fever report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Typhax in Typhoid Fever Drug Details: Typhax (ViCRM-197) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – KUR-502 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KUR-502 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KUR-502 in Diffuse Large B-Cell Lymphoma Drug Details: KUR-502 is...
-
Product Insights
Typhoid Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Typhoid Fever - Drugs In Development, 2023’, provides an overview of the Typhoid Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Typhoid Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Streptococcal Pneumonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Streptococcal Pneumonia - Drugs In Development, 2023’, provides an overview of the Streptococcal Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Drugs In Development, 2023’, provides an overview of the Clostridioides difficile Infections (Clostridium difficile Associated Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MVX-01 in Streptococcal Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MVX-01 in Streptococcal Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MVX-01 in Streptococcal PneumoniaDrug Details:MVX-01 is under development for the prevention and treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Typhax
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Typhax Drug Details Typhax (ViCRM-197) is under development for the prevention of typhoid fever. ...
-
Product Insights
Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections – Drugs In Development, 2022, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape. Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus...
-
Product Insights
Typhoid Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Typhoid fever pipeline market research report provides comprehensive information on the therapeutics under development for Typhoid Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Typhoid Fever and features dormant and...